首页 | 官方网站   微博 | 高级检索  
     

从肺论治法和从肠论治法对克罗恩病大鼠肺与结肠VIP含量的影响比较
引用本文:杨舒,王新月,杨雪,景姗,朱陵群,王硕仁.从肺论治法和从肠论治法对克罗恩病大鼠肺与结肠VIP含量的影响比较[J].世界科学技术-中医药现代化,2012,14(4):1841-1846.
作者姓名:杨舒  王新月  杨雪  景姗  朱陵群  王硕仁
作者单位:1. 北京中医药大学东直门医院消化内科 北京 100700
2. 北京中医药大学东直门医院中医内科学教育部重点实验室 北京 100700
基金项目:国家重点基础研究发展计划“( 973 计划”)项目(2009CB522705):基于炎症性肠病肺支气管病损出发的肺与大肠相表里关系研究,负责人:王新月。
摘    要:目的:观察从肺论治法和从肠论治法对克罗恩病大鼠肺与结肠中VIP含量的影响.方法:采用TNBS水溶液+无水乙醇一次灌肠法建立克罗恩病大鼠模型,分别灌胃从肺论治方(黄芪桔梗汤)和从肠论治方(黄芪黄连汤)进行实验性治疗,然后于0周、3周两个时间点测定肺和结肠血管活性肠肽(VIP)含量变化.结果:0周时,模型组肺VIP低于正常组,但无统计学差异.3周时,模型组肺VIP较正常组明显降低,各治疗组肺VIP较模型组升高明显(P<0.01),但西药组VIP升高较少,与正常组相比亦存在显著差异(P<0.05).模型组结肠VIP在0周和3周时均显著高于正常组(P<0.01).各治疗组3周时结肠VIP与模型组相比明显降低(P<0.01),且各组间无统计学差异.结论:CD肺损伤的机制可能与神经-内分泌-免疫网络失调有关,尤其是VIP这一神经肽的分泌失调.中药从肺论治方和从肠论治方均能通过调节VIP分泌,减轻肺及结肠组织的炎性反应,而且从肺论治方在上调肺组织中VIP表达,从而改善肺血管功能,调节肺组织局部血供,促进损伤修复方面优势突出.

关 键 词:克罗恩病  从肺论治法  从肠论治法  血管活性肠肽  肺损伤  机制
收稿时间:2011/9/10 0:00:00
修稿时间:2011/11/7 0:00:00

Comparison between Effects of Traditional Chinese Medicine Treatment from the Lung and Treatment from the Intestine on the Level of VIP in Rats with Crohn's Disease
Yang Shu,Wang Xinyue,Yang Xue,Jing Shan,Zhu Lingqun and Wang Shuoren.Comparison between Effects of Traditional Chinese Medicine Treatment from the Lung and Treatment from the Intestine on the Level of VIP in Rats with Crohn's Disease[J].World Science and Technology-Modernization of Traditional Chinese Medicine,2012,14(4):1841-1846.
Authors:Yang Shu  Wang Xinyue  Yang Xue  Jing Shan  Zhu Lingqun and Wang Shuoren
Affiliation:Department of Digestive Diseases, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 100700, China;Ministry of Education Key Laboratory of Traditional Chinese Internal Medicine, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 100700, China
Abstract:This study was aimed to observe effects of traditional Chinese medicine (TCM) treatment from the lung and treatment from the intestine on the level of VIP in rats with Crohn's disease. Rrat model of Crohn's disease was established by TNBS/ethanol enema. The model rats were treated experimentally from the lung (Huangqijiegeng Decoction) and from the intestine (Huangqihuanglian Decoction), respectively, by gastric perfusion. Changes in the level of VIP in rats with Crohn's disease were detected in zero, and three weeks after the treatment, respectively. The results showed that in zero week, the level of VIP in the lung of model group was decreased compared with that in normal control group, but there was no obvious difference. In the third week after treatment, the level of VIP in the lung of model group was significantly decreased compared with that in normal control group. And in different treatment groups the level of VIP in lung was significantly increased (P < 0.01),but there was obvious difference between Sulfasalazine group and normal control group (P < 0.05). In the zero and third week, the level of VIP in colon in model group was significantly increased compared with that in the normal control group (P < 0.01).In the third week, the level of VIP in colon in different treating group was significantly decreased compared with that in model group (P < 0.01). There was no obvious difference among the level of VIP in all treatment groups in the experiment. It was concluded that the imbalance of neuro-endocrineimmune network is the possible mechanism of lung injury in Crohn's disease, especially the imbalance expression of VIP. Both treatment from lung group (Huangqijiegeng Decoction) and from intestine group (Huangqihuanglian Decoction) can adjust the expression of VIP and relieve inflammatory reactions in the lung and colon. Treatment from the lung group (Huangqijiegeng Decoction) has an advantage in increasing the level of VIP in the lung, and improving the function of pulmonary vascular, adjusting local blood supply in lung tissues, and improving damage repair.
Keywords:Crohn's disease  treatment from lung  treatment from intestine  vasoactive intestinal peptide  lung injury  mechanism
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《世界科学技术-中医药现代化》浏览原始摘要信息
点击此处可从《世界科学技术-中医药现代化》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号